Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-23

Study Completion Date

2019-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cancer incidence is increasing with age and the likelihood of elderly suffering from cancer is 1:3. Although many clinical trials include elderly patients, no results for this subgroup of patients are available. Since there is no specific recommendations for treatment of elderly patients with pancreatic cancer, treatment with gemcitabine alone is the treatment of choice for these patients.

Single-agent gemcitabine is the current standard of care, but the addition of cytotoxic and targeted agents to gemcitabine has almost invariably provided no significant survival improvement.

Results obtained recently in the MPACT phase III clinical trial in patients with pancreatic cancer treated with nab-paclitaxel combined with gemcitabine have shown improvement in overall survival, but due to in this clinical trial was included patients between 27 and 88 years, it is considered necessary to conduct a specific study for patients over 70 years.

The aim of this study is to investigate whether the clinical benefit of nab-paclitaxel associated with gemcitabine can be extended to elderly patients with pancreatic cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer

NCT02382263

Advanced Pancreatic Cancer

COMPLETED PHASE1/PHASE2

Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer

NCT03807999

Pancreatic Neoplasm

COMPLETED PHASE2

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

NCT04233866

Metastatic Pancreatic Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8

ACTIVE_NOT_RECRUITING PHASE2

A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

NCT02993731

Carcinoma, Pancreatic Ductal

COMPLETED PHASE3

Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer

NCT02174887

Pancreatic Adenocarcinoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Carcinoma Metastatic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nab-paclitaxel plus Gemcitabine

Nab-paclitaxel 125 mg/m2 plus Gemcitabine 1000 days 1, 8 \& 15 in a 28 days cycle

Group Type EXPERIMENTAL

Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4

Intervention Type DRUG

Nab-paclitaxel 125 mg/m2 days 1,8 \& 15 in a 28 days cycle

Gemcitabine 1000 weeks 1,2,3/4

Intervention Type DRUG

Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4

Nab-paclitaxel 125 mg/m2 days 1,8 \& 15 in a 28 days cycle

Intervention Type DRUG

Gemcitabine 1000 weeks 1,2,3/4

Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nab-paclitaxel Gemcitabine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically-confirmed pancreatic adenocarcinoma
* Stage IV disease (metastatic only)
* No prior systemic therapy for their diagnosis (except in adjuvant setting \> six months previously)
* ECOG performance status of 0-1
* Age \>=70 years.
* Evidence of either or both of the following:

* RECIST-defined measurable disease (lesions that can be accurately measured in at least one dimension with the longest diameter \>= 20mm using conventional techniques or \>= 10 mm with spiral CT scan)
* An elevated serum CA19-9 at baseline ( \>= 2X ULN)
* Female patients must be either surgically sterile or postmenopausal.
* Male patients must be surgically sterile or must agree to use a condom during sex with women who may become pregnant while receiving the study drug and for 6 months after receiving the last dose.
* Adequate bone marrow function:

* ANC \>= 1500/uL
* platelet count \>= 100,000/uL
* hemoglobin \>= 9.0 g/dL
* Adequate hepatic function:

* Total bilirubin \<= 1.5 X ULN
* AST (SGOT) \<= 2.5 X ULN
* ALT (SGPT) \<= 2.5 X ULN
* Adequate renal function as determined by either:

* Serum creatinine \<= 1.5 X ULN
* Calculated or measured creatinine clearance \>= 40 mL/min (for calculated creatinine clearance, Cockroft-Gault equation will be used).
* Ability to understand the nature of this study protocol and give written informed consent
* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria

* Any prior systemic or investigational therapy for metastatic pancreatic cancer.
* Inability to comply with study and/or follow-up procedures.
* History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that, in the opinion of the investigator, renders the subject at high risk from treatment complications or might affect the interpretation of the results of the study.
* Presence of central nervous system or brain metastases.
* Life expectancy \< 12 weeks.
* Pregnancy (positive pregnancy test) or lactation.
* Prior malignancy except for adequately treated basal cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other form of cancer from which the patient has been disease-free for 5 years.
* Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.
* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.
* Known, existing uncontrolled coagulopathy.
* Pre-existing sensory neuropathy \> grade 1.
* Major surgery within 4 weeks of the start of study treatment, without complete recovery.
* Concurrent/pre-existing use of anticoagulant treatment.

Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No